Page 8 - Benjamin Pinsky News Today

The US is way behind on tracking COVID-19 variants Tara Santora © Provided by Popular Science By sequencing samples from COVID-19 patients, epidemiologists can track the virus as it mutates. New COVID-19 variants are turning up around the world—but none have made headlines like the so-called UK variant. The mutated form of the virus emerged across the pond in mid-December, and has already been found in 24 US states, totaling 293 cases, according to the Centers for Disease C...

"Our numbers are down overall in the hospital," said Dr. Colwell, Chief of Emergency Medicine at ZSFG. Mayor London Breed tweeted, "San Franciscos COVID-19 reproductive rate is back under 1, at 0.99! That means for every person who gets COVID-19, on average theyre passing it to less than one other person. Were slowing the spread. If this continues, we could soon start reopening under CAs guidelines." San Franciscos COVID-19 reproductive rate is back under 1, at 0.99! That means for every perso...

Stanford Medicine launches large-scale surveillance of coronavirus variants in Bay Area Stanford Medicine researchers are screening diagnostic samples to identify known coronavirus variants circulating in the Bay Area, including those from the United Kingdom, South Africa and Brazil. Jan 21 2021 Benjamin Pinsky is the medical director of the Stanford Clinical Virology Laboratory, where researchers are screening samples for known coronavirus variants circulating in the Bay Area. Stev...

Updated Dec 28, 2020 | 10:05 IST A study suggests that coronavirus antibodies wane significantly within several months of infection and preferentially target a different part of the virus in mild cases than in comparison to severe ones. COVID-19 severity is affected by the proportion of antibodies targeting crucial viral protein | Photo Credit: Pixabay&nbsp Washington: Coronavirus antibodies wane significantly within several months of infection and preferentially target a...

COVID-19 severity is affected by proportion of antibodies targeting crucial viral protein ANI | Updated: Dec 27, 2020 22:21 IST Washington [US], December 27 (ANI): Coronavirus antibodies wane significantly within several months of infection and preferentially target a different part of the virus in mild cases than in comparison to severe ones, suggest the findings of a new study. The findings which were published in Science Immunology identifies new links b...

Study reveals COVID-19 severity is affected by proportion of antibodies targeting crucial viral protein ANI | Updated: Dec 25, 2020 09:48 IST Washington [US], December 25 (ANI): A recent study has revealed that COVID-19 antibodies wane significantly within several months of infection and preferentially target a different part of the virus in mild cases of COVID-19 than in comparison to severe ones. The findings which were published in Science Immunology ide...

COVID-19 antibodies preferentially target a different part of the virus in mild cases of COVID-19 than they do in severe cases, and wane significantly within several months of infection, according to a new study by researchers at Stanford Medicine.

 E-Mail COVID-19 antibodies preferentially target a different part of the virus in mild cases of COVID-19 than they do in severe cases, and wane significantly within several months of infection, according to a new study by researchers at Stanford Medicine. The findings identify new links between the course of the disease and a patients immune response. They also raise concerns about whether people can be re-infected, whether antibody tests to detect prior infection may underestimate the bread...

$3.7 million NIH grant supports development of biosensor technology for diagnosing viral diseases For over ten years, Ali Yanik has been working to develop novel biosensor technology to provide rapid, low-cost testing for disease diagnostics and precision medicine. Now, with a five-year, $3.7 million grant from the National Institutes of Health, he and his collaborators are poised to complete the development and validation of a prototype and begin testing it in the field for detection of dengue...

 E-Mail For over ten years, Ali Yanik has been working to develop novel biosensor technology to provide rapid, low-cost testing for disease diagnostics and precision medicine. Now, with a five-year, $3.7 million grant from the National Institutes of Health, he and his collaborators are poised to complete the development and validation of a prototype and begin testing it in the field for detection of dengue fever, yellow fever, and Zika virus infections. "Were confident in being able to do thi...